RT Journal Article SR Electronic T1 18F-FDG PET as a Tool to Predict the Clinical Outcome of Infliximab Treatment of Rheumatoid Arthritis: An Explorative Study JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 77 OP 80 DO 10.2967/jnumed.110.076711 VO 52 IS 1 A1 Ernst H. Elzinga A1 Conny J. van der Laken A1 Emile F.I. Comans A1 Ronald Boellaard A1 Otto S. Hoekstra A1 Ben A.C. Dijkmans A1 Adriaan A. Lammertsma A1 Alexandre E. Voskuyl YR 2011 UL http://jnm.snmjournals.org/content/52/1/77.abstract AB 18F-FDG PET is a sensitive, promising method for visualizing disease activity in rheumatoid arthritis. This study aimed to assess the association between changes in 18F-FDG joint uptake after 2 wk of infliximab treatment and clinical outcome. Methods: Scans were obtained at the initiation of treatment and at 2 wk. Uptake in metacarpophalangeal and wrist joints was quantified using standardized uptake values. Results: Changes in mean standardized uptake value at 0–2 wk significantly correlated with the disease activity score (DAS) at 14 and 22 wk and contributed significantly to the prediction of DAS at these time points. No significant correlation was found between changes in acute-phase reactants at 0–2 wk and the DAS at later time points. Conclusion: Early changes in 18F-FDG uptake in joints during infliximab treatment of rheumatoid arthritis patients, using PET, may predict clinical outcome.